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In traditional cuban medicine, pomegranate fruits have been used to treat acidosis, dysentery, 
microbial infections, diarrhoea, helminthiasis; haemorrhage and respiratory pathologies [Vuorela 
et al., 2003; Roig, 1974; Jimenez et al., 1979; Seoane, 1984].Pomegranates contain high levels of 
Polyphenolic compounds, which are largely responsible for the fruit’s antioxidant properties. A 
number of studies have demonstrated that polyphenolic complexes derived from other plants 
have antiviral effects, suggesting that antiviral activity may also reside in the polyphenol (PP) 
fraction of pomegranates.  
The decay of organic matter generates an extremely heterogeneous mixture of organic molecules 
referred to as humic substances. They are sub-classified on the basis of solubility characteristics. 
The Fulvic Acid (FA) fraction of humic substances includes a variety of low molecular acidic 
molecules that are soluble in water under all pH conditions. Antiviral activity of fulvic acid 
containing Secomet V against poxviruses and SARS has been demonstrated [Kotwal et al., 
2006]. 
The current study was undertaken to evaluate the direct anti-influenza virus activity of 
pomegranate constituents present in Pomegranate Extracts: Pomegranate Juice (PJ) Pomegranate 
Liquid Extract (POMxl), Pomegranate Polyphenol enriched Powder Extract (POMxp) and Fulvic 
Acid (FA). Both Pomegranate Extracts and Fulvic Acid had anti-influenza activity. With regard 
to Pomegranate Extracts, all of the extracts had rapid antiviral activity when combined with 
influenza virus. The acidity of PJ and POMxl solutions contributed to anti-influenza activity, but 




temperature with > 200 μg/ml PPs substantially reduced the infectivity of H1N1, H3N2, and 
H5N1 influenza viruses. Generally, the loss of infectivity was accompanied by loss of 
hemagglutinating activity. Electron microscopic examination of influenza particles neutralized  
by PP treatment identified a coating of amorphous material and some damage to virion integrity. 
Reassortant H5N1 viruses derived from avian isolates were less affected by PP treatment, 
indicating that PP susceptibility is modulated by small changes in surface glycoproteins. Our 
analysis supports the development of pomegranate-derived PPs as natural, rapidly active, broad-
spectrum anti-influenza agents. Our finding demonstrates rapid anti-influenza virus activity in 
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Viruses are obligate intracellular parasites, which contain little more than bundles of gene strands 
of either RNA or DNA, and may be surrounded by a lipid-containing envelope [Wagner and 
Hewlett, 1999]. Unlike bacterial cells, which are free-living entities, viruses utilize the host cell 
environment to propagate new viruses. They use the reproductive machinery of cells they invade 
causing ailments as benign as a common wart, as irritating as a cold, or as deadly as what are 
known as the bloody African fever. The viruses that cause Lassa fever and Ebola fever and the 
retrovirus that causes acquired immunodeficiency syndrome (AIDS) are examples of viruses that 
spread easily, kill sometimes swiftly, and for which there is no cure or vaccine [Peter 1994]. 
Enveloped viruses like HIV, HBV, HCV, influenza and herpes viruses together contribute 
annually to over a billion infections and significant mortality worldwide. 
Viruses have numerous invasion strategies. Each strain of virus has its own unique configuration 
of surface molecules [Wagner and Hewlett, 1999]. These surface molecules work like keys in a 
lock, enabling viruses to enter into hosts by precisely fitting the molecules on their surfaces to 
those on the membranes of target cells. The success of viruses in evolution has been assured by 
four general attributes: genetic variation, variety in means of transmission, efficient replication 
within host cells, and the ability to persist in the host [Wagner and Hewlett, 1999]. As a 
consequence viruses have adapted to all forms of life and have occupied numerous ecological 
niches resulting in widespread diseases in humans, livestock and plants. 
Vaccine:  
 
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine  
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typically contains a small amount of an agent that resembles a microorganism. The agent 
stimulates the body's immune system can more easily recognize and destroy any of these 
microorganisms that it later encounters. Vaccines can be prophylactic (e.g. to prevent or 
ameliorate the effects of a future infection by any natural pathogen), or therapeutic (e.g. vaccines 
against cancer are also being investigated). The term vaccine derives from Edward Jenner's 1796 
use of the term cow pox which, when administered to humans, provided them protection against 
smallpox. Control of viral infections, like any other kind of infection control, can be affected 
either as a prophylactic measure or therapeutically, in order to control and alleviate a viral 
infection, which has already been established in the host. Unlike bacterial, fungal and parasitic 
infections, viruses are not autonomous organisms and therefore, require living cells in which to 
replicate. Consequently, most of the steps in their replication involve normal cellular metabolic 
pathways, and this makes it difficult to design a treatment to attack the virion directly, or its 
replication, without accompanying adverse effects on the infected cells [Wagner and Hewlett, 
1999]. We do have vaccine and there have been some remarkable success stories. Smallpox has 
been eradicated. Polio has been controlled; and many once common childhood viral infections 
are rare. But Vaccines are not available for all viruses. There are viral infections that are poorly 
controlled by vaccination; HIV is the example of viral disease that does not have an effective 
vaccine. And there are the influenza viruses which mutate and change with time and this requires 
frequent modification of vaccine composition. Genetic diversity and hypermutation contribute to 
difficulties in developing a vaccine against viruses like HIV and influenza. There are currently 
no known immune correlates of protection against HIV. This has made the development of a 
vaccine against HIV that would provide sterilizing immunity in the near future an impossible  
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task. The abandonment of a recent AIDS vaccine human trial due to a failure to elicit a protective 
sterilizing immune response confirms that empirical attempts to develop a vaccine may result in 
failures. Also the difficulty in predicting the next pandemic strain of influenza may make it 
difficult to respond rapidly should there be an outbreak. And there are emerging viruses, which 
appear from nowhere and these viruses cause problems before we have a chance to develop and 
test vaccines. The example would be the emergence of the SARS Corona virus. Another example 
is the avian influenza viruses like H5N1 jumping directly from birds to humans. Common cold 
caused by a very large number of different viruses and it is impossible develop vaccines to all of 
them. 
 
Antiviral Drugs:  
 
Antiviral drugs are a class of medication used specifically for treating viral infections. Like 
antibiotics for bacteria, specific antivirals are used for specific viruses. Most of the antivirals 
now available are designed to help deal with HIV, herpes viruses, the hepatitis B and C viruses, 
which can cause liver cancer, and influenza A and B viruses. Designing safe and effective 
antiviral drugs is difficult, because viruses use the host's cells to replicate. This makes it difficult 
to find targets for the drug that would interfere with the virus without also harming the host 
organism's cells. The emergence of antivirals is the product of a greatly expanded knowledge of 
the genetic and molecular function of organisms, allowing biomedical researchers to understand 
the structure and function of viruses, major advances in the techniques for finding new drugs, 
and the intense pressure placed on the medical profession to deal with the human 
immunodeficiency virus (HIV), the cause of the deadly acquired immunodeficiency syndrome  
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(AIDS) pandemic. Almost all anti-microbials, including anti-virals, are subject to drug resistance 
as the pathogens mutate over time, becoming less susceptible to the treatment. For instance, 
influenza viruses rapidly develop resistance to antivirals when they are used extensively.  
The ongoing HIV pandemic and the emergence of avian influenza viruses represent enormous 
challenges to worldwide control by vaccination and the currently available antivirals. These 
examples emphasize the importance of investigating all sources for potential antiviral drugs and 
particularly the largely unexplored resource of natural substances. An excellent outcome would 
be the identification of materials that are active against a range of different viruses, in contrast to 
vaccines and some antiviral drugs that target specific viral types. 
Influenza Virus: 
 
The first influenza virus to be isolated was from poultry, when in 1901 the agent causing a 
disease called ―fowl plague" was shown to be able to pass through a Chamberland filter, which 
has pores that are too small for bacteria to pass through. [Heinen, 2003]. The etiological cause of 
influenza, the Orthomyxoviridae family of viruses, was first discovered in pigs by Richard Shope 
in 1931 [Shimizu, 1997] .This discovery was shortly followed by the isolation of the virus from 
humans by a group headed by Patrick Laidlaw at the Medical Research Council of the United 
Kingdom in 1933. [Laidlaw et al., 1933] However, it was not until Wendell Stanley first 
crystallized tobacco mosaic virus in 1935 that the non-cellular nature of viruses was appreciated. 
 
Classification of influenza virus:  
 
In virus classification the influenza virus is an RNA virus of the family Orthomyxoviridae  
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[Kawaoka, 2006], which comprises five genera - Influenza virus A, Influenza virus B, Influenza 
virus C, Isa virus and Thogotovirus  
Influenza virus A 
 
This genus has one species, influenza A virus. Wild aquatic birds are the natural hosts for a large 
variety of influenza A. Occasionally; viruses are transmitted to other species and may then cause 
devastating outbreaks in domestic poultry or give rise to human influenza pandemics [Klenk et 
al., 2008].  The type A viruses are the most virulent human pathogens among the three influenza 
types and cause the most severe disease. The influenza A virus can be subdivided into different 
serotypes based on the antibody response to these. Influenza A viruses are classified into 
subtypes based on antibody responses to HA and NA. These different types of HA and NA form 
the basis of the H and N distinctions in, for example, H5N1. [Hilleman, 2002] There are 16 H 
and 9 N subtypes known. 
  
Influenza virus B 
 
This genus has one species, influenza B virus. Influenza B almost exclusively infects humans 
[Hay et al., 2001] and is less common than influenza A. The only other animals known to be 
susceptible to influenza B infection are the seal [Osterhaus et al., 2000] and the ferret [Clive 
Sweet et al., 1994]. This type of influenza mutates at a rate 2–3 times lower than type A 
[Nobusawa and Sato,2006] and consequently is less genetically diverse, with only one influenza 
B serotype [Hay et al., 2001].  
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Influenza virus C 
 
This genus has one species, influenza C virus, which infects humans, dogs and pigs, sometimes 
causing both severe illness and local epidemics [Matsuzaki et al, 2002] [Taubenberger & 
Morens, 2008]. However, influenza C is less common than the other types and usually seems to 
cause mild disease in children [Matsuzaki et al, 2006][ Homma et al., 1983]. 
Structure and Properties of the virus: 
 
Influenza viruses A, B and C are very similar in overall structure. [International Committee on 
Taxonomy of Viruses, 2006]. The virus particle is 80–120 nanometers in diameter and usually 
roughly spherical. The viral particles of all influenza viruses are similar in composition [Palese 
and Bouvier, 2008]. These are made of a viral envelope containing two main types of 
glycoproteins, wrapped around a central core. The central core contains the viral RNA genome 
and other viral proteins that package and protect this RNA.Its genome is not a single piece of 
nucleic acid; instead, it contains seven or eight pieces of segmented negative-sense RNA, each 
piece of RNA contains either one or two genes [Palese and Bouvier, 2008] . For example, the 
influenza A genome contains 11 genes on eight pieces of RNA, encoding for 11 proteins: 
hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), M1, M2, NS1, NS2 (NEP), PA, 
PB1, PB1-F2 and PB2 [Salzberg et al, 2005] . Hemagglutinin (HA) and neuraminidase (NA) are 
the two large glycoproteins on the outside of the viral particles. HA is a lectin that mediates 
binding of the virus to target cells and entry of the viral genome into the target cell, while NA is 
involved in the release of progeny virus from infected cells, by cleaving sugars that bind the 
mature viral particles [Suzuki, 2005].Thus, these proteins are targets for antiviral drugs [Wilson 
and von Itzstein, 2003]. Furthermore, they are antigens to which antibodies can be raised.  
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Viruses can only replicate in living cells [Helenius and Smith, 2004]. Influenza infection and 
replication is a multi-step process: firstly the virus has to bind to and enter the cell, then deliver 
its genome to a site where it can produce new copies of viral proteins and RNA, assemble these 
components into new viral particles and finally exit the host cell [Palese and Bouvier, 2008].  
Viruses bind through hemagglutinin onto sialic acid sugars on the surfaces of epithelial cells; 
typically in the nose, throat and lungs of mammals and intestines of birds [Klenk et al., 2002]. 




After the hemagglutinin is cleaved by a protease, the cell imports the virus by endocytosis 
[Steinhauer, 1999].Once inside the cell, the acidic conditions in the endosome cause two events 
to happen: first part of the hemagglutinin protein fuses the viral envelope with the vacuole's 
membrane, then the M2 ion channel allows protons to move through the viral envelope and 
acidify the core of the virus, which causes the core to dissemble and release the viral RNA and 
core proteins [Palese and Bouvier,2008]. 
The viral RNA (vRNA) molecules, accessory proteins and RNA-dependent RNA polymerase are 
then released into the cytoplasm These core proteins and vRNA form a complex that is 
transported into the cell nucleus, where the RNA-dependent RNA polymerase begins 
transcribing complementary positive-sense vRNA [Palese and Cros, 2003]. The vRNA is both 
exported into the cytoplasm and translated, or remains in the nucleus.  
Newly synthesised viral proteins are either secreted through the Golgi apparatus onto the cell 
surface  or transported back into the nucleus to bind vRNA and form new viral genome 
particles.Hemagglutinin and neuraminidase molecules cluster into a bulge in the cell membrane. 
The vRNA and viral core proteins leave the nucleus and enter this membrane protrusion. The 
mature virus buds off from the cell in a sphere of host phospholipid membrane, acquiring 
hemagglutinin and neuraminidase with this membrane coat [Nayak et al., 2004].  
As before, the viruses adhere to the cell through hemagglutinin; the mature viruses detach once 



























Antigenic drift is the gradual evolution of viral strains, due to frequent mutations [Both et al., 
1983]. It occurs on average every 2–8 years in response to selection pressure to evade human 
immunity [Smith et al., 2004; Plotkin et al., 2002; Koelle et al, 2006]. The process of antigenic 
drift is subtle, involving point mutations within antibody-binding sites in the HA protein, the NA 
protein, or both, which potentially occur each time the virus replicates [Finkenstadt et al., 2005; 
Koelle et al., 2006; Palese et al., 1991; Boni et al., 2004].  
Most of these mutations are neutral as they do not affect the conformation of the proteins; 
however, some mutations cause changes to the viral proteins such that the binding of host 
antibodies is affected. Consequently, infecting viruses can no longer be inhibited effectively by 
host antibodies raised to previously circulating strains, allowing the virus to spread more rapidly 
among the population [Webster and Webby, 2001]. Antigenic drift occurs in all strains of A and 
B viruses, although the observed evolutionary patterns vary dependent on the strain [Carrat and 
Flahault, 2007]. 
 
Antigenic Shift:  
 
Antigenic shift is only seen in influenza A viruses, and results from the replacement of HA (and 
less frequently NA) subtypes with novel ones [Cox and Subbarao, 2000]. This results in new 
viruses that have never been present in human circulation or last circulated decades before.  




epidemics and resulting in hundreds of thousands, or possibly millions, of influenza-related  
deaths [Treanor, 2004]. Antigenic shift is estimated to occur approximately three times every 
100 years [Potter, 2001], which is in line with the three antigenic shifts (and resulting 
pandemics) that occurred during the 20th century (1918, 1957 and 1968).  
An important process that contributes to major shifts in influenza antigenicity is genetic 
reassortment (mixing of genetic material between different viral strains) which occurs due to co-
circulation of different influenza A subtypes, and influenza B viruses. Although genetic 
reassortment can contribute to antigenic drift [Hay et al., 2004], it is primarily responsible for 
antigenic shift [Holmes, Ghedin, Miller, Taylor, Bao, et al., 2005; Holmes and Nelson, 2007]. 
Genetic reassortment is of particular importance in the evolution of A/H3N2 viruses [Schweiger 
et al., 2006], which emphasizes the need for comprehensive analysis of influenza viruses, 
particularly when considering the annual vaccine composition.  
Genetic reassortment is also possible between co-infecting influenza A subtypes from different 
species, a process that has the potential to create new subtypes with substantial antigenic changes 
that can result in an influenza pandemic.  
Thus, it is feasible that reassortment between human and avian virus strains will produce a 
virulent strain. Once a virus has undergone antigenic shift, it remains susceptible to antigenic 
drift, as occurs with any influenza virus. In fact, all current circulating influenza viruses are drift 















Influenza is a highly contagious, acute, febrile, respiratory disease attacking nose throat and 
lungs, which has been in circulation for centuries. The disease is caused by the influenza virus; 
Influenza has a high incidence in human populations and causes regular, large-scale morbidity 
and mortality. During seasonal epidemics, 5–15% of the worldwide population is typically 
infected, resulting in 3–5 million cases of severe illness and up to 500,000 deaths per year 
[WHO, 2003]. While all age groups are affected by the disease, most influenza-related 
hospitalization in industrialized countries occur in young children (<5 years of age) and in the 
elderly (≥65 years of age) [Advisory Committee on Immunization Practices Prevention and 
Control of Influenza, 2006] and most deaths occur among the elderly (≥65 years of age) [Kendal 
and Lui, 1987]. Seasonal flu occurs because the virus gradually changes as it spreads through a  
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population. As a result, our immunity to the virus becomes less and we become susceptible to 
infection again. Once every 10 – 50 years, a completely new influenza virus spreads to the 
human population. Humans have no immunity and the virus spreads worldwide causing a 
pandemic. The disease can be very severe and there can be more than one million deaths, the 
worst influenza pandemic occurred in 1918 and killed 40 – 50 million people. Taking into 
account work absenteeism as well as direct medical costs, the annual economic impact of 
influenza in the US has been estimated to be as high as US $12–14 billion [Monto, 2000]. The 
human population is currently contending with the most recent influenza pandemic, caused by an 
H1N1 virus that apparently spread to humans from a swine reservoir [Garten et al., 2009]. 
Although this does not represent the introduction of a novel subtype into the human population, 
the newly emergent H1N1 virus carries surface glycoproteins (perhaps particularly the H1) that 
are substantially different from those of recently circulating H1N1 viruses. Consequently, a high 
proportion of humans have little immunity to the new virus. Thus, influenza continues to have a 




People who contract influenza are most infective between the second and third days after 
infection and infectivity lasts for around ten days [Carrat et al., 2006]. Influenza can be spread in 
three main ways: by direct transmission when an infected person sneezes mucus into the eyes, 
nose or mouth of another person; through people inhaling the aerosols produced by infected 
people coughing, sneezing and spitting; and through hand-to-mouth transmission from either 
contaminated surfaces or direct personal contact, such as a hand-shake[Weber and Stilianakis,  
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2008][Hall, 2007] and they may all contribute to the spread of the virus [Tellier , 2006][Gardam 
et al., 2007]. In the airborne route, the droplets that are small enough for people to inhale are 0.5 
to 5 µm in diameter and inhaling just one droplet might be enough to cause an infection [Weber 
and Stilianakis, 2008]. Although a single sneeze releases up to 40,000 droplets, [Cole and Cook, 





It can be difficult to distinguish between the common cold and influenza in the early stages of 
these infections [Eccles, 2005], but flu can be identified by a high fever with a sudden onset and 
extreme fatigue. Symptoms of influenza can start quite suddenly one to two days after infection. 
Usually the first symptoms are chills or a chilly sensation, but fever is also common early in the 
infection, with body temperatures ranging from 38-39 °C (approximately 100-103 °F) [Suzuki et 
al., 2007].Many people are so ill that they are confined to bed for several days, with aches and 
pains throughout their bodies, which are worse in their backs and legs. Symptoms of influenza 
may include: body aches, especially joints and throat, extreme coldness and fever, fatigue, 






Vaccination against influenza with an influenza vaccine is often recommended for high-risk 
groups, such as children and the elderly, or in people who have asthma, diabetes, or heart 
disease. The effectiveness of these influenza vaccines is variable. Due to the high mutation rate  
      15 
  
of the virus, a particular influenza vaccine usually confers protection for no more than a few 
years. Every year, the World Health Organization predicts which strains of the virus are most 
likely to be circulating in the next year, allowing pharmaceutical companies to develop vaccines 
that will provide the best immunity against these strains [WHO, 2006]. It is possible to get 
vaccinated and still get influenza. The vaccine is reformulated each season for a few specific flu 
strains but cannot possibly include all the strains actively infecting people in the world for that 
season. It takes about six months for the manufacturers to formulate and produce the millions of 
doses required to deal with the seasonal epidemics; occasionally, a new or overlooked strain 
becomes prominent during that time and infects people although they have been vaccinated (as 
by the H3N2 Fujian flu in the 2003–2004 flu season) [Holmes, Ghedin, Miller, Taylor, Bao, et 
al., 2005]. It is also possible to get infected just before vaccination and get sick with the very 
strain that the vaccine is supposed to prevent, as the vaccine takes about two weeks to become 




Anti Viral Drugs:  
 
The two classes of antiviral drugs used against influenza are neuraminidase inhibitors and M2 




Antiviral drugs such as oseltamivir (trade name Tamiflu) and zanamivir (trade name Relenza) 
are neuraminidase inhibitors that are designed to halt the spread of the virus in the body  
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[Moscona, 2005].These drugs are often effective against both influenza A and B [Stephenson 
and Nicholson, 1999]. 
M2 inhibitors (adamantanes) 
 
The antiviral drugs amantadine and rimantadine block a viral ion channel (M2 protein) and 
prevent the virus from infecting cells [Pinto and Lamb, 2006]. These drugs are sometimes 
effective against influenza A if given early in the infection but are always ineffective against 
influenza B because B viruses do not possess M2 molecules [Stephenson and Nicholson, 1999]. 
Influenza is a highly communicable acute respiratory disease, predisposes to a number of 
complications, resulting in a severe worldwide economic burden. Even though, prevention and 
control of both the annual influenza epidemics and its infrequent but severe pandemic outbreaks 
are achieved by the use of vaccines and newly emerging antiviral drugs, these vaccines provide 
sometimes lower than desirable protection, particularly in the immunocompromised and the 
elderly, the two most susceptible subpopulations [Keren et al., 1988; Admon et al., 1997]. 
Vaccines are generally unavailable in the early stages of a pandemic [WHO, 1999] and antiviral 
drugs are the only means of intervention. But these antiviral drugs are only 70 – 90 % effective 
and may shorten the duration of illness by 1.5 days when used within the first 48 hours [Treanor 
and Falsey, 1999; Hayden et al., 1999]. Also these antiviral drugs cause side effects in the hosts. 
So it is time to explore broad spectrum agents that can target either the lipid portion of the 
envelope or the sugar moieties of the glycoproteins or the rafts (regions within viral and cell 
envelopes where a higher concentration of the glycoproteins exist). Broad spectrum agents that 
can serve as disrafters or neutralize the viral infectivity by binding to the envelope lipid or sugar  
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moieties will not be affected by the vagaries of hypermutation of surface antigens. This is 
because the post-translation modification is a host function. The side effects caused by the 
antiviral drugs in the infected individuals (lactic acidosis, peripheral neuropathy and adipose 
deposition) are difficult to manage and there is an urgent need for alternate prophylactic and 
treatment approaches that can be easily delivered, are nontoxic, and are unaffected by the rapid 
mutation rates of the virus. Shikimic acid, one of the main starting materials of Tamiflu is 
obtained from star anise, a cooking spice from a tree grown in China but other sources of 
shikimic acid are being explored and fairly high concentrations of it are found in natural sources, 
e.g. pine, spruce and fir trees [Kotwal, 2008]. In a recent article, additional problems related to 
the use of shikimic acid, developments and the problems toward the synthesis of Tamiflu and the 
use of other starting materials have been discussed[Farina and Brown,2006].Complex molecules 
like lectins and mucins which can interfere with the attachment of enveloped viruses also seem 
to have a broad spectrum antiviral activity against HIV and poxviruses [Mall et al.,2006; Habte 
et al., 2007; Kaur et al.,2007]. These agents can be predicted to be effective against influenza but 
that remains to be proved and they may not be too practical because of their molecular size and 
due to interference of normal tissue functions, other than as possible additives to microbicides. 
Therefore a wonderful outcome would be the identification of materials, particularly the largely 
unexplored resource of natural substances that are active against a range of different viruses, in 
contrast to vaccines and some antiviral drugs that target specific viral types. 
Antiviral Activity of Natural Substances: 
 
Recently, both Pomegranate Juice and Fulvic Acid have been shown to inactivate genetically  
diverse strains of influenza including H5N1, further confirming the broad spectrum nature of  
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these agents [Kotwal, 2008].A number of studies have demonstrated that polyphenolic 
complexes derived from other plants have antiviral effects against DNA and RNA viruses 
[Serkedjieva and Manolova, 1992; Nakayama et al., 1993; Weiss et al., 2005; Ehrhardt et al., 
2007; Schnitzler et al., 2008], suggesting that antiviral activity in pomegranates may also reside 
in the PP fraction. It is clear from some studies that plant PPs can exert an antiviral effect by 
interacting directly with viral particles [Nakayama et al., 1993; Song et al., 2005; Ehrhardt et al., 
2007; Schnitzler et al., 2008], although the extent of PP binding to viral surface components may 
be influenced by the nature of the virus [Serkedjieva, 2003; Ehrhardt et al., 2007]. Plant PPs may 
also exert antiviral effects during intracellular replication [Palamara et al., 2005]. In part, this 
may be due to PPs opposing the pro-oxidant state induced in cells by the replication of some 
viruses [Fraternale et al., 2009].Also studies have shown that cranberry juice contains high 
molecular weight materials (NDM) that inhibit bacterial adhesion to host cells as well as the co-
aggregation of many oral bacteria. Because of its broad-spectrum activity, researchers 
investigated NDM's potential for inhibiting influenza virus adhesion to cells, and subsequent 
infectivity. Their findings have indicated that the inhibitory effect of NDM on influenza virus 
adhesion and infectivity may have a therapeutic potential [Weiss et al., 2005]. 
Many traditional medicinal plants have been reported to have strong antiviral activity and some 
of them have already been used to treat animals and people who suffer from viral infection 
[Hudson, 1990; Venkateswaran et al., 1987; Thyagarajan et al., 1988, 1990]. Research interests 
for antiviral agent development was started after the Second World War in Europe and in 1952 
the Boots drug company at Nottingham, England, examined the action of 288 plants against 
influenza A virus in embryonated eggs. They found that 12 of them suppressed virus  
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amplification [Chantrill et al., 1952]. Canadian researchers in the 1970s reported antiviral 
activities against herpes simplex virus (HSV), poliovirus type 1, coxsackievirus B5 and 
echovirus 7 from grape, apple, strawberry and other fruit juices [Konowalchuk and Speirs, 
1976a,b, 1978a,b]. One hundred British Columbian medicinal plants were screened for antiviral 
activity against seven viruses [McCutcheon et al., 1995]; twelve extracts were found to have 
antiviral activity at the concentrations tested. The extracts of Rosa nutkana and Amelanchier 
alnifolia were very active against an enteric corona virus. A root extract of Potentilla arguta and 
a branch tip extract of Sambucus racemosa completely inhibited respiratory syncytial virus 
(RSV). An extract of Ipomopsis aggregata demonstrated good activity against parainfluenza 
virus type 3. 
In addition to these, extracts prepared from Cardamine angulata, Conocephalum conicum, 
Lysichiton americanum, Polypodium glycyrrhiza and Verbascum Thapsus exhibited antiviral 
activity against herpes virus type 1. The extracts of 40 different plant species have been used in 
traditional medicine and were investigated for antiviral activity against a DNA virus, human 
cytomegalovirus (HCMV), and two RNA viruses, Ross River virus (RRV) and poliovirus type 1, 
at noncytotoxic concentrations [Semple et al., 1998]. The most active extracts were the aerial 
parts of Pterocaulon sphacelatum (Asteraceae) and roots of Dianella longifolia var. grandis 
(Liliaceae), which inhibited poliovirus type 1 at concentration of 52 and 250 μg ml 
-1
, 
respectively. The same authors concluded that the extracts of Euphorbia australis 
(Euphorbiaceae) and Scaevola spinescens (Goodeniaceae) were the most active against HCMV 
whilst, extracts of Eremophila latrobei subsp. glabra (Myoporaceae) and Pittosporum 
phylliraeoides var. microcarpa (Pittosporaceae) exhibited antiviral activity against RRV.The  
      20 
  
human rotavirus (HRV), RSV and influenza A virus were susceptible to a liquid extract from 
Eleutherococcus senticosus roots. In contrast, the DNA viruses, adenovirus and HSV type 1 
virus (HSV-1) were not inhibited by the same plant extract [Glatthaar-Saalmuller et al., 2001]. 
They concluded that the antiviral activity of Eleutherococcus senticosus extract is viral RNA 
dependant. Related studies also showed that influenza RNA was inhibited by a water-soluble 
extract of Sanicula europaea (L.) [Turan et al., 1996]. In a later study [Karagoz et al., 1999], it 
was shown that an acidic fraction obtained from the crude extract of Sanicula europaea was the 
most active fraction in inhibiting human parainfluenza virus type 2 replication at noncytotoxic 
concentrations. 
Another example, Myrcianthes cisplatensis showed in vitro anti-RSV but not anti-HSV-1 or anti-
adenovirus serotype 7 (DNA virus) [Kott et al., 1999]. In contrast, other medicinal plants, for 
example Nepeta coerulea, Nepeta nepetella, Nepeta tuberosa, Sanguisorba minor magnolii and 
Dittrichia viscose showed clear antiviral activity against DNA and RNA viruses, i.e. HSV-1 and 
VSV in addition to poliovirus type 1 in the case of Dittrichia viscose [Abad et al., 2000]. The 
Azadirachta indica leaf extract was found to be active against a number of viruses such as 
smallpox (DNA), chicken pox (DNA), poxvirus (DNA), poliomyelitis (RNA) and herpes viruses 
(DNA) [Rao et al., 1969; Kaii-a-Kamb et al., 1992]. An extract of the cactus plant Opuntia 
streptacantha inhibited intracellular DNA and RNA virus replication and inactivated 
extracellular virus, such as HSV, equine herpes virus, pseudorabies virus and influenza virus 
[Ahmad et al., 1996]. The Bergenia ligulata, Nerium indicum and Holoptelia integrifolia plants 
exhibited considerable antiviral activities against influenza virus (RNA) and HSV (DNA) 
[Rajbhandari et al., 2001]. 
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The antiviral properties of marine algae have been addressed [Chamorro et al., 1996; Siddhanta 
et al., 1997; Berge et al., 1999; Nicoletti et al., 1999]. Preclinical testing suggests that Spirulina, 
a unicellular filamentous cyanobacteria (formerly called blue green algae), has several 
therapeutic attributes such as cholesterol regulation, immunological, antiviral and antimutagenic 
properties [Chamorro et al., 1996]. Strain-specific antiinfluenza virus inhibitory activity, based 
on the reproduction of influenza viruses in tissue cultures, was reported for marine algae of the 
Bulgarian Black Sea coast [Serkedjieva et al., 2000]. 
Polyphenols and the proanthocyanidins extracted from Hamamelis virginiana bark and two new 
hydrolysable tannins, shephagenins A and B, isolated along with hippophaenin A and strictinin 
from the leaf extract of Shepherdia argentea, showed a remarkable inhibitory activity against 
HSV-1 [Erdelmeier et al., 1996] and HIV-1 reverse transcriptase (RT) [Yoshida et al., 1996]. 
The inhibitory effect of the Shepherdia argentea leaf extract on HIV-1 RT was found to be 
caused by tannins, and their activities were stronger than that of (-))epigallocatechin gallate as a 
positive control [Yoshida et al., 1996].  
In an early study of plant viral infection, Cadman [Cadman,1960] , suggested that polyphenolic 
extracts of the leaf of Rubus idaeus (raspberry) probably act against most viruses by clumping 
the virus particles together into complexes, which are largely noninfective. Hudson [Hudson, 
1990], deduced that viral inactivation in vitro is directly attributable to preferential binding of the 
polyphenol to the protein coat of the virus, whereas, in a systematic study of the antiviral activity 
of a very wide range of natural products, Van den Berghe et al. [Van den Berghe et al., 1986] 
concluded that polyphenols act principally by binding to the virus and/or the protein of the host 
cell membrane and thus arrest absorption of the virus. Sakagami [Sakagami et al., 1995], have 
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put forward a number of possible mechanisms whereby polyphenols may exert their antiviral 
action. They suggested that the major part of the antiviral activity in polyphenols probably 
derives from their direct inactivation of the virus and/or from inhibition of the virus binding to 
the cells. They also noted that although polyphenols are known to inhibit viral replication 
enzymes (such as RT for HIV and RNA polymerase for influenza virus) and other enzymes (e.g. 
poly (ADP-ribose) glycohydrolase), these effects seem to be rather nonspecific. The most 
pronounced in vitro selectivity of anti-influenza and anti-herpes type 1 and type 2 actions were 
confirmed against polyphenolic complexes isolated from the Bulgarian medicinal plant 
Geranium sanguineum (L.) [Serkedjieva and Hay, 1998; Serkedjieva and Ivancheva, 1999]. 
Although polyphenols were shown to have a broad antiviral spectrum in vitro, their 
corresponding properties in vivo have not been well established [Sakagami et al., 1995]. 
The bioflavonoids comprise a large family of plantderived polyphenolic compounds of low 
molecular weight, which exhibit diverse biological activities. The naturally occurring benzo-d 
pyrone derivatives and phenylchromones are widely distributed throughout the plant kingdom, as 
components in fruits, vegetables, tea, grains, bark, roots, stems and flowers. Up to several 
hundred milligrams are consumed daily in the average Western diet. On balance, a considerable 
body of evidence suggests that plant flavonoids may be health promoting, disease-preventing 
dietary compounds [Middleton, 1998]. They are the basis of many traditional folk remedies 
which have many important biochemical effects, some of which have been applied in human 
therapy, as described in the review by Havsteen [Havsteen,1983], and are now being increasingly 
used as prototypes for the development of specific drug therapies [Berger et al., 1992]. 
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The antiviral activities of bioflavonoids extracted from medicinal plants have been evaluated 
[Beladi et al., 1977; Tsuchiya et al., 1985]. The black tea flavonoid, theaflavin is a well-known 
antioxidant with free radical-scavenging activity and it was able to neutralize bovine rotavirus 
and bovine corona virus infections [Clark et al., 1998].  
The flavonoid chrysosplenol C is one of a group of compounds known to be a potent and specific 
inhibitor of picornaviruses and rhinoviruses, the most frequent causative agents of the common 
cold [Semple et al., 1999]. The Dianella longifolia and Pterocaulon sphacelatum were found to 
contain flavonoid chrysosplenol C and anthraquinone chrysophanic acid, respectively, which 
inhibit the replication of poliovirus types 2 and 3 (Picornaviridae) in vitro [Semple et al., 1999, 
2001]. Recently, new flavonol glycoside - the iridoid glycosides and three phenylpropanoid 
glycosides, named luteoside A, luteoside B and luteoside C  were isolated from Barleria prionitis 
and from the roots of the medicinal plant Markhamia lutea, respectively, and shown to have 
potent in vitro activity against RSV [Chen et al., 1998; Kernan et al., 1998]. In another study, 
five groups of biflavonoids (amentoflavone, agathisflavone, robustaflavone, rhusflavanone and 
succedaneflavanone) were isolated from medicinal plants of Rhus succedanea and Garcinia 
multiflora, and exhibited various antiviral effects against a number of viruses including 
respiratory viruses (influenza A, influenza B, parainfluenza type 3, RSV, adenovirus type 5 and 
measles) and herpes viruses (HSV-1, HSV-2, HCMV and varicella zoster virus, VZV) [Lin et al., 
1999]. Amentoflavone and robustaflavone demonstrated significant activity against anti-HSV-1 
and anti-HSV-2 with only moderate anti-HSV- 2 from rhusflavanone. A significant anti 
influenza A and B activity was achieved by amentoflavone, robustaflavone and agathisflavone. 
By comparison, rhusflavanone and succedaneflavanone were found to produce a selective anti- 
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influenza type B only. The inhibitory activities against measles and VZV were demonstrated 
with rhusflavanone and succedaneflavanone, respectively. In general, none of groups of 
biflavonoids exhibited anti-HCMV [Lin et al., 1999].  
Baicalein (BA), a flavonoid compound purified from the medicinal plant Scutellaria baicalensis 
Georgi, has been shown to possess anti-inflammatory and anti-HIV-1 activities. BA may 
interfere with the interaction of HIV-1 envelope proteins with chemokine co-receptors and block 
HIV-1 entry of target CD4 cells and BA could be used as a basis for developing novel anti-HIV-
1 agent [Li et al., 2000].Morin is another type of flavonoid group extracted from Maclura 
cochinchinensis that exhibited a powerful anti-HSV-2 activity in contrast with a synthetized 
morin pentaacetate that was inactive [Bunyapraphatsara et al., 2000]. This would suggest that 
free hydroxyl groups are required for anti-HSV-activity, as demonstrated previously for the 
antiviral activity of other flavonoids [Hudson, 1990; Bunyapraphatsara et al., 2000]. Such studies 
clearly indicate that antiviral activity varies with the compound and the virus. 
The mechanisms of binding the flavonoids extracted from medicinal plants received less 
attention. However, one stage of viral replication that may be inhibited by flavonoids is viral 
DNA synthesis. For example, SP-303 exhibited strong activity against herpes virus (HSV-1 and 
HSV-2) [Barnard et al., 1993]. Most of the potent anti-HIV flavonoids such as BA, quercentin 
and myricetin have shown inhibitory activity not only against the virus-associated RT but also 
against cellular DNA or RNA polymerase [Ono and Nakane, 1990].The inhibition of DNA and 
RNA polymerase by these flavonoids was extensively analysed to elucidate the inhibition 
mechanism(s) by Ono and Nakane [Ono and Nakane, 1990]. Once again the degree of inhibition 
also varied depending on the flavonoid [Jassim and Naji, 2003]. 
 




Origin and History: 
 
Punica granatum L., the pomegranate belongs to the Punicacea family [Harde et al., 1970] and is 
one of the oldest edible fruits. It has been cultivated extensively in Mediterranean countries, Iran, 
India and to some extent in the U.S. (California), China, Japan and Russia. Iran is a native land 
of the pomegranate which is grown in every area, both coastal and mountainous areas. 
Introduced into Latin America and California by spanish settlers in 1769, pomegranate is now 
cultivated in parts of California and Arizona for juice production. 
 
Climate: 
Pomegranates can be grown in tropical to warm temperate climates. However, the best quality 
pomegranate fruits are produced in regions with cool winters and hot, dry summers. 
Pomegranates vary in frost tolerance, but in some cases temperatures down to 10°F may not 
severely injure the plants.  
Pomegranate Tree: 
Normally a dense, bushy, deciduous shrub, 2-4 m (6-12 ft.) tall, the plant has slender, somewhat 
thorny branches. It may be trained as a small tree reaching 7 m (20 ft.) in height. Pomegranate is 
an attractive ornamental. 
Pomegranate Leaves: 
Pomegranate leaves are glossy, dark green, oblong to oval, 2.5-3 cm (1-1.25 in.) long. Leaves are 
arranged opposite or nearly so and clustered on short branchlets. 





Blooms are a flaming orange-red, 4-6 cm (1.5-2.5 in.) in diameter with crinkled petals and 
numerous stamens. Flowers are borne solitary or in small clusters angled towards the end of 
branchlets. 
Pomegranate Fruit: 
Pomegranates are brownish-yellow to purplish-red berries 5 - 12 cm (2-5 in.) in diameter with a 
smooth, leathery skin. Fruits are spherical, somewhat flattened, with a persistent calyx. The calyx 
may be 1-6 cm (1.5-2.5 in.) long. Numerous seeds are each surrounded by a pink to purplish-red, 
juicy, pulp (arils) which is the edible portion. The pulp is somewhat astringent. 
 
 
Figure 4: Schematic illustration of Pomegranate fruit parts [Aviram et al., 2008].   
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Benefits of Pomegranate: 
The pomegranate fruit has a long history of traditional use as a folk remedy. Recent research has 
associated constituents of the fruit with a variety of medical benefits. Cardiovascular benefits, 
antiatherosclerotic effects, and inhibition of tumor initiation and growth have been attributed to 
the potent antioxidative activity of pomegranate components [Aviram et al., 2008; de Nigris et 
al., 2005; Ignarro et al., 2006; Adams et al., 2006; Malik et al., 2005].  
Pomegranates contain high levels of polyphenolic compounds; including hydrolysable tannins 
(mainly punicalagin) and plant flavonoids such as the anthocyanins, which are largely 
responsible for the fruit’s antioxidant properties [Gil et al., 2000; Tzulker et al., 2007].  
Pomegranate Juice is a source of potent polyphenolic antioxidants (tannins, anthocyanins) which 
are considered to be anti-atherogenic. Athererogenesis involves lipoproteins modifications and 
arterial macrophage foam cell formation.  
Invitro studies demonstrated a significant dose-dependent antioxidant capability of PJ against 
lipid peroxidation in plasma (by up to 33%), in low density lipoprotein (LDL, by up to 43%), and 
in high density lipoprotein (HDL, by up to 22%). Researchers have analyzed and compared 
polyphenols content and ability to reduce LDL oxidation of several juices obtained from fruits.  
Pomegranate juice (wonderful variety) was found to have 6.1+/- 0.4 mM of total polyphenols in 
comparison to cranberry juice, red wine, blueberry juice, green tea and orange juice.  







most potent antioxidant against LDL oxidation followed by cranberry juice, red wine, blue berry 
juice, green tea and orange juice, which were less potent than pomegranate juice by 10%, 13%, 
30%, 40% and 70% respectively.  
Pomegranate juice is the most potent antioxidant against LDL oxidation and this effect could be 
related to its high polyphenolic flavonoids content as well as to the specific potent flavonoids 
present in pomegranate juice such as tannins and anthocyanins. Researchers have demonstrated 
that a very potent anti-atherogenicity of pomegranate juice consumption which could be 
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Pomegranate juice is neuroprotective in an animal model of neonatal hypoxic-ischemic brain 
injury. In this research paper, they determined whether protection of the neonatal brain against a 
hypoxic-ischemic insult could be attained through supplementation of the maternal diet with 
pomegranate juice, notable for its high polyphenol content. Dietary supplementation with 
pomegranate juice resulted in markedly decreased brain tissue loss (60%) in all three brain 
regions (hippocampus, cortex and striatum) assessed, with the highest pomegranate juice dose 
having greatest significance (p _ 0.0001). Pomegranate juice also diminished caspase-3 
activation by 84% in the hippocampus and 64% in the cortex. These results demonstrate that 
maternal dietary supplementation with pomegranate juice is neuroprotective for the neonatal 
brain. [Holtzman et al., 2005] 
Pomegranate juice is effective against prostate cancer. Research has determined the effects of 
Pomegranate juice consumption on prostate-specific antigen (PSA) progression in men with a 
rising PSA following primary therapy. A clinical trial for men with rising PSA after surgery or 
radiotherapy was conducted. Patients were treated with 8 ounces of pomegranate juice daily 
(wonderful variety, 570 mg total polyphenol gallic acid equivalents) until disease progression. 
Mean PSA doubling time significantly increased with treatment from a mean of 15 months at 
baseline to 54 months post treatment .In vitro assays comparing pretreatment and post treatment 
patient serum showed a12% decrease in cell proliferation and a17% increase in apoptosis, a 23% 
increase in serum nitric oxide, and significant reductions in oxidative state and sensitivity to 
oxidation of serum lipids after versus before pomegranate juice consumption [Pantuck et al., 
2006]. 
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Pomegranate components also have growth inhibiting activity against diverse microorganisms. 
Direct antibacterial, antifungal, and antiplasmodial activity was demonstrated for pomegranate 
polyphenol (PP) fractions [Reddy et al., 2007]. 
Pomegranate peel extracts contains substantial amounts of polyphenols such as ellagic tannins, 
ellagic acid and gallic acid. It has been used in the preparation of tinctures, cosmetics, 
therapeutic formulae and food recipes [Nasr, Ayed, &Metche, 1996].In a study the researchers 
dried pomegranate peels and they were powdered and extracted in a soxhlet extractor with ethyl 
acetate (EtOAc), acetone, methanol and water for 4 h each. The dried extracts were used to 
determine their antioxidant capacity by the formation of phosphomolybdenum complex and 
antimutagenicity against the mutagenicity of sodium azide by the ames test. All the peel extracts 
exhibited marked antioxidant capacity, but the water extract was the lowest. All the extracts 
decreased sodium azide mutagenicity in Salmonella typhimurium strains (TA100 and TA1535), 
either weakly or strongly. At 2500 mg/plate all the extracts showed strong antimutagenicity. The 
antimutagenicity of the water extract was followed by acetone, EtOAc and methanol extracts. 
The overall results showed that the pomegranate peel extracts have both antioxidant and 
antimutagenic properties and may be exploited as biopreservatives in food applications and 
neutraceuticals [Jena et al., 2002]. 
Binding by a pomegranate component to the viral envelope glycoprotein of HIV-1 blocked 
interaction with cell receptors and inhibited infection, but the chemical nature of the active 











The decay of organic matter generates an extremely heterogeneous mixture of organic molecules 
(referred to as humic substances) that are sub-classified on the basis of solubility characteristics.  
The Fulvic Acid (FA) fraction of humic substances includes a variety of low molecular acidic 
molecules that are soluble in water under all pH conditions 
 
The hypothetical model structure of Fulvic acid (Buffle's model) contains both aromatic and 






Figure 7:  The model Structure of Fulvic Acid [Buffle’s model].  










Substances  % dry ash-free basis  
C H O N 
Fulvic acids  44 - 49  3,5 - 5,0  44 - 49  2,0 - 4,0 
Humic acids  52 - 62  3,0 - 5,5  30 - 33  3,5 - 5,0 
Proteins  50 - 55  6,5 - 7,3  19 - 24  15,0 - 19,0 
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Benefits of Fulvic acid: 
 
A formulation called Secomet V has been reported to have a broad spectrum antiviral properties 
[Kotwal et al., 2006] and was subsequently revealed a year later by Stefan Coetzee from 
Fulvimed Pvt. Ltd. to have Fulvic Acid as the major active ingredient. A network of researchers 
have been investigating the antiviral properties of a formulation called Secomet V, whose active 
ingredient is fulvic acid, which is a complex mixture of compounds arising from decomposing 
organic matter. Antiviral activity of fulvic acid containing Secomet V against poxviruses and 
SARS has been demonstrated [Kotwal et al., 2006]. 
Fulvic acid has anti-inflammatory and antimicrobial effects and lends itself particularly to topical 
applications, such as for psoriasis and eczema. Research has described the anti-inflammatory 
properties in a mouse model of contact hypersensitivity as well as in atopic dermal reactions in 
humans [Snyman et al., 2002; Van Rensburg, Malfeld, and Dekker, 2001; Van Rensburg, Van 
Straten, and Dekker 2000]. Fulvic acid has been approved as a veterinary treatment for dogs and 
cats suffering from pyotraumatic dermatitis or eczema. Although it is not yet clear how exactly 
fulvic acid works, preliminary results indicate that it scavenges free radicals and inhibits specific 
phagocytic and lymphocytic cellular functions. The people involved in fulvic acid research 
always appear to have a direct or indirect connection to the now defunct Enerkom. For example, 
Pfeinsmith Ltd, the overseas company that bought the entire portfolio of Enerkom’s intellectual 
property rights – some 128 patents in total – granted the exploitation of this intellectual property 
in Africa to the South African company that arranged the sale. This company is now called 
Secomet. (www.secomet.com). It operates out of the Techno Park in Stellenbosch near Cape 
Town. Secomet has identified a new source of fulvic acid, based on carbohydrates derived from  
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plants. The advantage of deriving fulvic acid from what is essentially a food source is that unlike 
coal it does not contain traces of toxic metals such as magnesium, chrome, or aluminum. These 
levels may be very low in fulvic acid derived from coal. Secomet markets a variety of extracts 
based on fulvic acid. It had the anti-microbial efficacy of the plant extracts it uses tested in vitro 
by the School of Child & Adolescent Health at the University of Cape Town. The lab reported 
growth inhibitions of 16 bacterial organisms to each of the four plant extracts tested, and 
recommended further research into the active component [www.secomet.com]. In addition, in 
2005 Secomet contracted ViroLogic, a lab in California, to evaluate its product against ten 
strains of HIV in vitro. In vitro work undertaken at the Department of Medical Virology at the 
University of Cape Town also confirmed antiretroviral activity. 
A possible antiviral effect of FA was raised by early studies demonstrating the inhibition of 
bacteriophage adsorption by FA [Bixby and O’Brien, 1979]. However, the potential of FA as an 
antiviral has received little attention, perhaps because of the difficulty in isolating standardized 
FA preparations from natural materials. More recently, high quality FA generated from defined 
starting materials by controlled oxidative processes [Bergh et al.,1997] has been shown to have 
broad in vitro antimicrobial activity[Van Rensburg, Van Straten, and Dekker, 2000], as well as 
anti-inflammatory activity following topical application[Van Rensburg, Malfeld, and Dekker, 
2001]. Coal-derived humic acids and oxyfulvic acid, which are complex mixtures formed during 
the decomposition of organic matter including cellulose found naturally have been previously 
shown to have anti-HIV properties [Van Rensburg, Dekker, Weis, Smith T-L, Rensburg E.J and 
Schneider, 2002] and [ Van Rensburg, Van Straten, and J. Dekker, 2000].  
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Our work with pomegranates developed from a small project in the laboratory when we were 
evaluating the in vitro antiviral activity of plant decomposition product - Fulvic Acid. We first 
included pomegranate juice in these experiments, and we were surprised to find that the juice had 
anti-influenza virus activity. This stimulated our interest in pomegranates and we evaluated the 
direct anti-influenza virus activity of three commercially available Pomegranate Extracts: 
Pomegranate Juice (PJ), Pomegranate Liquid Extract (POMxl), and a Pomegranate Polyphenol 
Powder Extract (POMxp). Extracts were prepared from California-grown and processed 




Objectives of this Study: 
 
1. The current study was undertaken to evaluate the direct anti-influenza virus activity of 
pomegranate constituents present in three commercially available Pomegranate Extracts: 
Pomegranate Juice (PJ), Pomegranate Liquid Extract (POMxl), and a Pomegranate 
Polyphenol Powder Extract (POMxp). 
 
2. We also evaluated the anti-influenza virus activity of Fulvic Acid. We used the formulation 
called Secomet V which was supplied by Dr.Girish.J. Kotwal. Even though we included FA 































































Pomegranates are one of the richest sources of plant polyphenols (PPs). Since antiviral activity 
has been attributed to plant PPs, we evaluated the anti-influenza activity of Pomegranate Juice 
(PJ).The current study was undertaken to evaluate the direct anti-influenza virus activity of 
pomegranate constituents present in commercially available pomegranate juice. A standard dose 
of infectious virus was incubated with the different concentration of pomegranate juice. Viral 
infectivity was measured by titration in susceptible MDCK cells, and hemagglutinating activity 
was determined using chicken red blood cells. Pomegranate juice had anti-influenza virus 
activity that was distinct from the effect of the acidic pH of the test materials. Our findings 




The high level of diverse polyphenolic compounds in pomegranates suggests that the fruit may 
be a rich source of molecules that exert antiviral activity via multiple mechanisms. Recently, 
evidence was presented that pomegranate PPs are directly virucidal for influenza viruses and also 
act at the intracellular level to inhibit influenza virus replication [Haidari et al., 2009]. In the 
current study, we investigated the direct anti-influenza virus activity of pomegranate juice. We 
demonstrate that components of the PP fraction of pomegranate juice rapidly inactivate influenza 
virus. Our findings suggest that inactivation is a consequence of PP interactions with the viral 
particles. 




2. Materials and Methods: 
 
2.1. Pomegranate Juice: 
Pomegranate juice was prepared from California-grown and processed wonderful variety 
pomegranates and supplied by POM Wonderful (Los Angeles, CA). 
Preparation of Wonderful Pomegranate Juice (PJ): 
 
Pomegranate juice was prepared from the whole fruit that was cut to expose arils during the 
squeezing process. The juice was filtered, pasteurized, concentrated to 65 Brix and stored at -18 
°C. Then, it was diluted 1:4 (v/v) to 16 Brix with water to obtain the single strength PJ which 
was used in the study [Aviram et al., 2008]. 
Chemical Composition of Pomegranate Juice: 
Total phenolics (GAE), 3600 μg/mL (0.36%), including mainly hydrolyzable tannins 
(ellagitannins), such as oligomers and punicalagin / punicalin, with smaller amounts of ellagic 
acid and anthocyanins (delphinidin, cyaniding, and pelargonidin) and their glycosides [Aviram et 
al., 2008]. 
 
2.2 Chicken Red Blood Cells: 
 
This reagent was stored in fridge. The 0.5% Chicken Red Blood Cells were prepared fresh in 
PBS each time we did the assay for hemagglutinating activity and stored it in ice until use.  
 
2.3 Phosphate buffered saline (PBS): 
 
We used PBS for diluting samples and Chicken Red Blood Cells 
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2.4 Citrate/Phosphate buffer: 
These buffers were prepared matching the pH of test solutions.     
  
2.5. Viruses and viral titration 
Experiments were performed using the following influenza A viruses: 
A/Puerto Rico/8/34 (H1N1) (PR8) and the reassortant virus A/HKx31 (H3N2) (x31), which 
expressed the H3 and N2 of A/Aichi/2/68 on the PR8 background [Kilbourne et al., 1971]. 
Influenza virus stocks were grown in the allantoic cavity of embryonated hen’s eggs and titers of 
infectious virus were measured by 50% tissue culture infective dose (TCID50) titration. Madin 
Darby canine kidney (MDCK) cells for viral titration were grown in MEM with L-glutamine (2 
mM), penicillin (100 IU/ml), streptomycin (100 g/ml), and gentamicin (10 g/ml), and 
supplemented with 10% FBS.  
Confluent MDCK cell monolayers in 96-well tissue culture plates were washed once with serum-
free MEM before use. Serial 10-fold dilutions of virus in serum-free MEM containing 0.3% BSA 
and 1 g/ml L-(toslyamido 2-phenyl) ethyl chloromethyl ketone (TPCK)-treated trypsin 
(Worthington, Lakewood, NJ) were incubated in replicate wells (200 l/well) for 2-3 d at 37°C 
with 5% CO2. Wells positive for virus growth were identified by the presence of 
hemagglutinating (HAg) activity in the supernatant, and 50% tissue culture infective dose 
(TCID50) titers were calculated by the method of Reed and Muench. 
2.6. Treatment of virus with Pomegranate Juice and evaluation of antiviral activity: 
Confluent monolayers of MDCK cells for viral titration were grown in 96-well tissue culture  





plates and were washed once with serum-free MEM before use. MEM containing 0.3% bovine 
serum albumin (Sigma) and 1 μg/ml L-(toslyamido 2-phenyl) ethyl chloromethyl ketone 
(TPCK)-treated trypsin [Worthington, Lakewood, NJ] was added to the wells and used for 
dilution of treated virus. Influenza virus at 5 x 10
7
 TCID50/ml was combined with different 
concentrations of PJ diluted in PBS, and incubated for 5 min at room temperature.  
Immediately following incubation, treated virus was serially diluted 10-fold in triplicate wells 
containing MDCK cell monolayers, and plates were incubated for 2 days at 37°C with 5% CO2. 
Wells positive for virus growth were identified by the presence of hemagglutinating activity in 
the supernatant by using a fresh 96-well round bottom plate. We transferred 50μl of supernatant 
from the original plate to the fresh 96-well round bottom plate, carefully not disrupting the 
MDCK monolayer at the bottom of the wells, from the top row to the bottom row of the plate. 
Added the 50μl of 0.5%CRBC to all the wells.  
The plates were briefly agitated with hand and set the plate on the bench for 30 minutes to one 
hour at room temperature. After the incubation, wells positive for virus growth were identified 
by the presence of hemagglutinating activity. In the absence of hemagglutinating activity, red 
blood cells roll to the bottom of the wells and form small round pellets, whereas no pellets are 
visible when the cells are agglutinated and 50% tissue culture infective dose (TCID50) titers 
were calculated by the method of Reed and Meunch. To control for antiviral effects due solely to 








3.1. Pomegranate Juice PPs eliminate influenza virus infectivity and hemagglutinating activity: 
 
Initial experiments tested PJ for direct antiviral activity against influenza x31 and PR8. The virus 
was treated for 5 min at room temperature with different concentrations of PJ and titers of  
infectious virus were determined immediately thereafter.  
A consistent trend was greater anti-influenza activity in PJ compared with the pH control, 





Table 2: This table shows the pH of different concentration of PJ, PomBlue Juice, Grape 
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Components pH 
Pomegranate Juice Neat 3.17 
20% Pomegranate Juice 3.7 
15% Pomegranate Juice 3.9 
10% Pomegranate Juice 4.3 
PomBlue Juice Neat 3.35 
50% PomBlue Juice  3.49 
20% PomBlue Juice 3.91 
15% PomBlue Juice 4.14 
10% PomBlue Juice 4.60 
Grape Juice Neat 3.27 
20% Grape Juice 3.88 
10% Grape Juice 4.99 
5% Grape Juice 6.33 
Coke Neat  2.42 















Figure 8: The antiviral activity of PJ against influenza virus.  
Influenza x31 (H3N2) at 5 x 10
7
 TCID50/ml was treated for 5 min at room temperature with 
different concentrations of PJ, or with a pH-matched buffer. Infectious virus titers after treatment 
were determined by TCID50 assay. Results are shown as the fold reduction in titer relative to 





































We compared anti-influenza virus activity of Pomegranate Blue Juice (PomBlue) against RGX31 
virus. We treated the RGX31 virus with 20%, 10% and 5% of PomBlue along with the virus 
treated with PBS (untreated virus). We observed that RGX31 virus treated PomBlue at the 
concentration of 20% in PBS completely eliminated infectivity. (Figure 9) 
When we were evaluating the anti-influenza virus activity of PJ against the influenza virus, we 





































































































       
 
We also did an infectivity assay with a different approach. We evaluated the anti-influenza virus 
activity of 2% PJ to 0% PJ. In this procedure, everything remained the same as the usual 
procedure for the assay for infectivity but here we did not treat the samples. Also we first added 
different concentration of PJ (from 2%, to 0%) in viral growth media, added to the wells of the 
monolayer of MDCK cells, then added the RGX31 virus in the first row and then did tenfold 
dilution from top row to the bottom. The rest of the procedure is the same as we used to do. We 




These results indicate that the acidity of PJ contributed to anti-influenza virus activity and also a 
greater anti-influenza virus activity in PJ compared with the pH control, indicating anti-viral 
activity was distinct from the effect of pH alone. The anti-viral activity of PJ must be due to 
polyphenol component because comparable PP concentrations in POMxp solutions and in PJ 
produced similar fold reductions in viral titers (10% PJ ≈ 360 μg/ml PPs), indicating that the 
antiviral activity demonstrated in PJ was primarily due to the PP component also be dependent 
on a direct interaction between polyphenols (PP) in PJ and the viral particles. 
Our analysis adds to the growing body of literature describing the antiviral activity of PP 
preparations derived from plants. We show that the PP component of pomegranate juice interacts  
directly with influenza virus particles and rapidly neutralizes infectivity. Previous studies 





for a direct interaction of PPs with the viral HA and NA [Ehrhardt et al., 2007; Nagai et al., 
1992; Nakayama et al., 1993; Serkedjieva and Manolova, 1992; Song et al., 2005]. 
PP preparations derived from plants are typically a complex mixture of molecular forms. There 
is evidence for differences in the antiviral activity of individual PP compounds [Haidari et al., 
2009] and synergistic activity by PP mixtures [Song et al., 2005]. Presumably, the biochemical 
reactivity of PPs and their interactions with proteins and lipids play an important role [Diniz et 
al., 2008; Soares et al., 2007]. However, the molecular interactions that are the basis for the 
antiviral activity of PPs and how these relate to the characteristics of specific PPs are not well 
understood [Song et al., 2005]. Our analysis emphasizes the possibility that PPs derived from 











































































Pomegranate are one of the richest sources of plant polyphenols (PPs), Since antiviral activity 
has been attributed to plant PPs, we evaluated the anti-influenza activity of Pomegranate Liquid 
Extract (POMxl).The current study was undertaken to evaluate the direct anti-influenza activity 
of pomegranate constituents present in Pomegranate Liquid Extract (POMxl). A standard dose of 
infectious virus was incubated with the different concentration of Pomegranate Liquid Extract 
(POMxl). Viral infectivity was measured by titration in susceptible MDCK cells. Pomegranate 
Liquid Extract (POMxl) had anti- influenza activity that was distinct from the effect of the acidic 
pH of the test materials. Our findings demonstrate rapid anti-influenza activity in Pomegranate 




Polyphenolic compounds present at a higher level in pomegranates suggests that the fruit may be 
a rich source of molecules that exert antiviral activity via multiple mechanisms. Research have 
shown that pomegranate PPs are directly virucidal for influenza viruses and also act at the 
intracellular level to inhibit influenza virus replication [Haidari et al., 2009]. In the current study, 
we investigated the direct anti-influenza virus activity of Pomegranate Liquid Extract. We 
demonstrate that components of the PP fraction of Pomegranate Liquid Extract rapidly inactivate 
influenza virus. Our findings suggest that inactivation is a consequence of PP interactions with 
the viral particles. 
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2. Materials and Methods: 
 
2.1 Pomegranate Liquid Extract (POMxl): 
Pomegranate Liquid Extract was prepared from California-grown and processed wonderful 
variety pomegranates and supplied by POM Wonderful (Los Angeles, CA). 
  
Preparation of Pomegranate Liquid Extract (POMxl): 
 
After expelling most of the juice from the pomegranate whole fruit, the remaining fruit (peels 
and membranes), which include aril residues, were collected and processed to remove the seeds 
before going through a screw press to produce a puree. The puree was enzymatically treated to 
break down the colloidal structure of the husks and to solubilize sugars, minerals, acids, and 
polyphenol compounds. The puree polyphenols were concentrated via membrane system and the 
resultant cloudy POMxl was filtered to produce a pomegranate polyphenol extract. The obtained 
extract was concentrated after passing through an evaporator and pasteurized. The final product 
has a 65–70 Brix concentration and was stored at 4°C [Aviram et al., 2008]. 
 
Chemical Composition of Pomegranate Liquid Extract (POMxl): 
Total phenolics (GAE), 130 000 μg/mL (13%), including mainly hydrolysable tannins 
(ellagitannins), such as oligomers and punicalagin/punicalin, with a smaller amounts of ellagic 
acid and anthocyanins (delphinidin, cyaniding, pelargonidin) and their glycosides other 
components: sugars, 52%; organic acid, 2.0%; ash, 2.0%(70 Brix) [Aviram et al., 2008]. 
 
2.2 Chicken Red Blood Cells: 
As described in Chapter 2 
       
      50 
  
2.3 Phosphate buffered saline (PBS): 
 
As described in Chapter 2 
 
2.4 Citrate/Phosphate buffer: 
As described in Chapter 2 
 
2.5. Viruses and viral titration: 
Experiments were performed using influenza A virus: Reassortant virus A/HKx31 (H3N2) (x31), 
which expressed the H3 and N2 of A/Aichi/2/68 on the PR8 background [Kilbourne et al., 1971]. 
Influenza virus stocks were grown in the allantoic cavity of embryonated hen’s eggs and titers of 
infectious virus were measured by 50% tissue culture infective dose (TCID50) titration. Madin 
Darby canine kidney (MDCK) cells for viral titration were grown in MEM with L-glutamine (2 
mM), penicillin (100 IU/ml), streptomycin (100 g/ml), and gentamicin (10 g/ml), and 
supplemented with 10% FBS.  
Confluent MDCK cell monolayers in 96-well tissue culture plates were washed once with serum-
free MEM before use. Serial 10-fold dilutions of virus in serum-free MEM containing 0.3% BSA 
and 1 g/ml L-(toslyamido 2-phenyl) ethyl chloromethyl ketone (TPCK)-treated trypsin 
(Worthington, Lakewood, NJ) were incubated in replicate wells (200 l/well) for 2-3 d at 37°C 
with 5% CO2. Wells positive for virus growth were identified by the presence of 
hemagglutinating (HAg) activity in the supernatant, and 50% tissue culture infective dose 
(TCID50) titers were calculated by the method of Reed and Muench. 
 




2.6. Treatment of virus with Pomegranate Liquid Extract and evaluation of antiviral activity: 
 
As described in Chapter 2 
 
3. Results: 
3.1. Pomegranate Liquid Extract PPs eliminate influenza virus infectivity and hemagglutinating 
activity: 
 
Initial experiments tested POMxl for direct antiviral activity against influenza x31. The virus was 
treated for 5 min at room temperature with different concentrations of POMxl and titers of 
infectious virus were determined immediately thereafter. A consistent trend was greater anti-
influenza activity in POMxl compared with the pH control (statistically significant for 2.5% 
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Pomegranate Liquid Extract (POMxl) pH 
20% POMxl 3.21 
15% POMxl 3.24 
10% POMxl 3.26 
5% POMxl 3.43 
2.5% POMxl 3.65 
1.25% POMxl 4.09 
0.625% POMxl 4.96 























Figure 10: The antiviral activity of POMxl against influenza virus.  
Influenza x31 (H3N2) at 5 x 10
7
 TCID50/ml was treated for 5 min at room temperature with 
different concentrations of POMxl, or with a pH-matched buffer. Infectious virus titers after 
treatment were determined by TCID50 assay. Results are shown as the fold reduction in titer 
















































These results indicate that the acidity of POMxl contributed to anti-influenza virus activity and 
also a greater anti-influenza virus activity in POMxl compared with the pH control (statistically 
significant for 2.5% POMxl), indicating anti-viral activity was distinct from the effect of pH 
alone. The anti-viral activity may also be dependent on a direct interaction between Polyphenols 
(PP) in POMxl and the viral particles. 
We show that the PP component of Pomegranates interacts directly with influenza virus particles 
and rapidly neutralizes infectivity. Previous studies demonstrating the anti-influenza activity of 
PPs from other plant sources have provided evidence for a direct interaction of PPs with the viral 
HA and NA [Ehrhardt et al., 2007; Nagai et al., 1992; Nakayama et al., 1993; Serkedjieva and 
Manolova, 1992; Song et al., 2005]. 
PP preparations derived from plants are typically a complex mixture of molecular forms. There 
is evidence for differences in the antiviral activity of individual PP compounds [Haidari et al., 
2009] and synergistic activity by PP mixtures [Song et al., 2005]. Presumably, the biochemical 
reactivity of PPs and their interactions with proteins and lipids play an important role [Diniz et 
al., 2008; Soares et al., 2007]. However, the molecular interactions that are the basis for the 
antiviral activity of PPs and how these relate to the characteristics of specific PPs are not well 
understood [Song et al., 2005]. PP binding to cell surface molecules have been described 
[Williamson et al., 2006]. Any therapeutic benefits due to the antiviral mechanism we describe 
are likely to require direct application of PPs at the site of infection [Droebner et al., 2007]. 
Studies of mouse models have shown that PP administration to the lung reduced the effects of  
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influenza infection without toxicity to the host [Droebner et al., 2007; Nagai et al., 1992; 
Serkedjieva et al., 2008]. Interestingly, nasopharyngeal administration of pomegranate extracts is 
a Cuban folk medicine remedy for influenza [Vidal et al., 2003]. Our analysis emphasizes the 
possibility that PPs derived from Pomegranate Liquid Extract and other plant sources may be 
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Pomegranates are one of the richest sources of plant polyphenols (PPs). Since antiviral activity 
has been attributed to plant PPs, we evaluated the anti-influenza activity of Pomegranate 
Polyphenol-enriched Powder Extract (POMxp).The current study was undertaken to evaluate the 
direct anti-influenza virus activity of pomegranate constituents present in Pomegranate 
Polyphenol-enriched Powder Extract (POMxp). A standard dose of infectious virus was 
incubated with the different concentration of filtered Pomegranate Polyphenol-enriched Powder 
Extract (POMxp). Viral infectivity was measured by titration in susceptible MDCK cells.  
Studies using POMxp showed that brief treatment at room temperature with > 200 μg/ml PPs 
substantially reduced the infectivity of H1N1, H3N2, and H5N1 influenza viruses. Generally, the 
loss of infectivity was accompanied by loss of hemagglutinating activity. Electron microscopic 
examination of influenza particles neutralized by PP treatment identified a coating of amorphous 
material and some damage to virion integrity. Reassortant H5N1 viruses derived from avian 
isolates were less affected by PP treatment, indicating that PP susceptibility is modulated by 
small changes in surface glycoproteins. Our analysis supports the development of pomegranate-





The high level of diverse polyphenolic compounds in pomegranates suggests that the fruit may 
be a rich source of molecules that exert antiviral activity via multiple mechanisms. Recently, 
evidence was presented that pomegranate PPs are directly virucidal for influenza viruses and also 
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act at the intracellular level to inhibit influenza virus replication [Haidari et al., 2009]. In the 
current study, we investigated the direct anti-influenza virus activity of Pomegranate Polyphenol-
enriched Powder Extract. We demonstrate that components of the PP fraction of Pomegranate 
Polyphenol-enriched Powder Extract rapidly inactivate different influenza virus subtypes, 
including emerging viruses with pandemic potential. Our findings suggest that inactivation is a 
consequence of PP interactions with the viral HA and NA, and may be substantially modulated 
by relatively small changes in these molecules. 
 
2. Materials and Methods: 
 
2.1 Pomegranate Polyphenol-enriched Powder Extract (POMxp): 
Pomegranate Polyphenol-enriched Powder Extract (POMxp) was prepared from California-
grown and processed wonderful variety pomegranates and supplied by POM Wonderful (Los 
Angeles, CA). 
  
Preparation of Pomegranate Polyphenol-enriched Powder Extract (POMxp): 
 
POMxl, diluted with water, was passed through a resin column, which preferentially 
absorbs polyphenols. Polyphenols adsorbed on the resin were recovered using ethanol in water. 
The recovered polyphenol solution was dried to produce POMxp [Aviram et al., 2008]. 
Chemical Composition of Pomegranate Polyphenol-enriched Powder Extract (POMxp): 
Total phenolics (GAE), 930 μg/mg (93%), including mainly hydrolyzable tannins (ellagitannins), 
such as oligomers and punicalagin/punicalin, with smaller amounts of ellagic acid and trace 
anthocyanins other components: sugars, 3.2%; organic acids, 1.9%; ash, 2.5%; protein, 5.0%;  
and moisture, 1.2%[Aviram et al., 2008].     
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2.2 Chicken Red Blood Cells: 
 
This reagent was stored in fridge. The 0.5% Chicken Red Blood Cells were prepared fresh in 
PBS / MEM containing 0.3% BSA / MEM containing 0.1% BSA each time we did the assay for 
hemagglutinating activity and stored it in ice until use.  
 
2.3 Phosphate buffered saline (PBS): 
 
We used PBS for both the assay for infectivity, the assay for hemagglutinating activity and 
toxicity assay. 
2.4. Viruses and viral titration 
Experiments were performed using the following influenza A viruses: 
A/Puerto Rico/8/34 (H1N1) (PR8) and the reassortant virus A/HKx31 (H3N2) (x31), which 
expressed the H3 and N2 of A/Aichi/2/68 on the PR8 background [Kilbourne et al., 
1971].[Haidari et al., 2009] Reassortant H5N1 viruses generated by reverse genetics (identified 
by the prefix rg) from A/Vietnam/1203/04 (VN/04), an isolate from a fatal human case, and from 
the avian isolates A/Duck/Hunan/795/02 (Dk/HN/02), A/Duck/Laos/3295/06 (Dk/LS/06), and 
A/Japanese White Eye/Hong Kong/1038/06 (JWE/HK/06). The reassortant H5N1 viruses were 
constructed with PR8 and expressed the H5 (from which polybasic amino acids that are 
associated with high virulence were removed) and N1 of the original isolates [Forrest et al., 
2009].  
Influenza virus stocks were grown in the allantoic cavity of embryonated hen’s eggs and titers of 
infectious virus were measured by 50% tissue culture infective dose (TCID50) titration. Madin 
Darby canine kidney (MDCK) cells for viral titration were grown in MEM with L-glutamine (2  
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mM), penicillin (100 IU/ml), streptomycin (100 g/ml), and gentamicin (10 g/ml), and 
supplemented with 10% FBS. Confluent MDCK cell monolayers in 96-well tissue culture plates 
were washed once with serum-free MEM before use. Serial 10-fold dilutions of virus in serum-
free MEM containing 0.3% BSA and 1 g/ml L-(toslyamido 2-phenyl) ethyl chloromethyl 
ketone (TPCK)-treated trypsin (Worthington, Lakewood, NJ) were incubated in replicate wells 
(200 l/well) for 2-3 d at 37°C with 5% CO2. Wells positive for virus growth were identified by 
the presence of hemagglutinating (HAg) activity in the supernatant, and 50% tissue culture 
infective dose (TCID50) titers were calculated by the method of Reed and Muench. 
 
2.5. Treatment of virus with Pomegranate Polyphenol enriched Powder Extracts and evaluation 
of antiviral activity 
 
POMxp was dissolved in PBS at a PP concentration of 4.0 mg/ml (= 4.3 mg/ml POMxp), passed 
through a 0.2 μm diameter filter, and diluted in PBS for testing. Influenza viruses at 5 x 10
7
 
TCID50/ml were combined with different concentrations of POMxp (expressed as PP 
concentration) and incubated for 5 min at room temperature. Immediately following incubation, 
titers of infectious virus were determined by the assay for viral infectivity or TCID50 assay as 
mentioned in Chapter 2 in MDCK cells.  
The HAg activity of influenza viruses was also evaluated immediately after treatment with 
different concentrations of POMxp as described above. Serial 2-fold dilutions of treated virus 
were prepared with PBS in 96-well round-bottom plates (50 μl/well). An equal volume of 0.5% 





agitated, and hemagglutination was scored after 30 min incubation at room temperature. POMxp  
alone at a PP concentration of 4 mg/ml had no HAg activity when the assay was performed in the 
presence of 0.15% BSA, as was the case in all experiments. In the absence of BSA, PP 
concentrations greater than approximately 50 μg/ml had inherent HAg activity. 
2.6. Electron Microscopy :( by Aarthi Sundararajan) 
 Influenza x31 was treated for 5 min at room temperature with different concentrations of 
POMxp and negatively stained for examination by transmission electron microscopy. Treated 
virus was adsorbed to freshly glow-discharged collodion and carbon films on 400 mesh copper 
grids, stained with 0.5% phosphotungstic acid, and examined with a Hitachi H-800 electron 
microscope at 75 kV. 
2.7 Evaluation of Toxicity of POMxp on MDCK cells: 
 
We evaluated the toxicity of different concentration of filtered POMxp on monolayers of MDCK 
cells. This was done to test if POMxp is toxic to MDCK cells. This assay is almost the same as 
the assay for infectivity described above. But we did several experiments by modifying the usual 
procedure each time we did the toxicity assay to see if POMxp is toxic to MDCK cells. We did 
not use the virus and we did not treat the samples at room temperature for 5 minutes. We used 6-
well / 24- well plates. We made filtered POMxp as mentioned above. We also tried dissolving 
POMxp in PBS / Serum Free Growth Medium. Then we made different concentration of filtered 
POMxp in PBS / Serum Free Growth Media by diluting in PBS / MEM1X with 0.3% BSA / 
MEM1X with 5% FBS. We added different concentration of filtered POMxp samples to the 
wells containing the monolayer of MDCK cells. The different concentration of filtered POMxp 
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we used was from 40% to .078%. Even though we tested different concentration POMxp from 
40% to .078%., most of the time we did toxicity assays with filtered POMxp concentration from 
4% and below. After samples were added to the wells containing the monolayers of MDCK 
cells, the plates were incubated for 24 / 48 hours at 37°C with 5% CO2.After incubation, initially 
we trypsinized cells and counted them and later on we just observed the MDCK cell monolayers 
with different concentration of filtered POMxp under the microscope.  
3. Results: 
3.1. Pomegranate Powder Extract PPs eliminate influenza virus infectivity and hemagglutinating 
activity 
 
Initial experiments tested POMxp for direct antiviral activity against influenza x31. The virus 
was treated for 5 min at room temperature with different concentrations of PP-enriched POMxp. 
Test solutions of POMxp in PBS (Table 4) were at near-neutral pH, and matching pH control 
solutions had no effect on viral infectivity (not shown). Exposure of influenza x31 to > 100 
μg/ml PPs rapidly reduced infectivity, with titers being lowered by more than 4 logs at 800 μg/ml 
(Figure 11). Control experiments established that the low PP levels in culture medium during 
titration of treated virus samples had no effect on MDCK cell viability or on TCID50 titers (not 
shown). Thus, antiviral activity was dependent on a direct interaction between PPs and viral 
particles. To determine whether pomegranate PPs had antiviral activity against other influenza 
subtypes, we evaluated the activity of POMxp solutions against PR8 (H1N1) (by Aarthi 
Sundararajan)(Figure 12). As was the case for x31 (H3N2) (Figure 11), infectivity was rapidly 
eliminated by treatment with > 100 μg/ml PPs. 
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Pomegranate Powder Extract (POMxp) pH 
40% POMxp 6.48 
20% POMxp 6.70 
10% POMxp 6.82 
5% POMxp 6.87 
2.5% POMxp 6.89 





















Figure 11: The antiviral activity of POMxp against influenza virus x31. 
Influenza x31 (H3N2) was treated for 5 min at room temperature with different concentrations of 
POMxp (expressed as PP concentration). Infectious virus titers measured by TCID50 assay were 
































































Figure 12: The antiviral activity of POMxp against influenza virus PR8.  
Influenza PR8 (H1N1) was treated for 5 min at room temperature with different concentrations 
of POMxp (expressed as PP concentration). Infectious virus titers measured by TCID50 assay 
were determined after treatment. 
 
Influenza virus-induced hemagglutination results from binding of the viral HA to sialic acid 
residues on RBC surface molecules and reflects RBC cross-linking by intact virions. To 
determine the effect of POMxp treatment on the HAg activity of x31, viral preparations were 
treated as described above for the analysis of effects on viral infectivity. Hemagglutination titers 
were measured immediately following incubation with POMxp solutions. A loss of HAg activity 
accompanied the loss of infectivity of x31, raising the possibility of PP interactions with the viral 















































Figure 13: The antiviral activity of POMxp against influenza virus x31.  
Influenza x31 (H3N2) was treated as above with different concentrations of POMxp (expressed 
as PP concentration). Infectious virus titers (filled squares, left axis) and hemagglutination titers 
(open squares, right axis) were determined after treatment.       
 
Influenza virus-induced hemagglutination results from binding of the viral HA to sialic acid 
residues on RBC surface molecules and reflects RBC cross-linking by intact virions. To 
determine the effect of POMxp treatment on the HAg activity of PR8, viral preparations were 
treated as described above for the analysis of effects on viral infectivity. Hemagglutination titers 
were measured immediately following incubation with POMxp solutions. A loss of HAg activity  
accompanied the loss of infectivity of PR8 (Figure 14) as with x31(Figure13), raising the 















































Figure 14: The antiviral activity of POMxp against influenza virus PR8.  
Influenza PR8 (H1N1) was treated as above with different concentrations of POMxp (expressed 
as PP concentration). Infectious virus titers (filled squares, left axis) and hemagglutination titers 
(open squares, right axis) were determined after treatment. 
 
3.2. Pomegranate PPs mask influenza virus envelope glycoproteins :( by Aarthi Sundararajan) 
 
To gain insights into the mechanism of PP effects on influenza viruses, POMxp-treated and 
control influenza x31 particles were examined by transmission electron microscopy (Figure 15 
A,B,C). Treated virions remained largely intact, but some damage to virion integrity was also 
evident. In addition, treated virions were surrounded by amorphous material that was increased 
in density after treatment with higher PP concentration. 
 





































Figure 15 A, B, C: The electron micrographs of influenza x31 after treatment with POMxp. 
Virus at 5 x 10
8
 TCID50/ml was incubated for 5 min at room temperature with PBS (A), 800 




       
3.3. Influenza virus variants differ in susceptibility to pomegranate PPs:  (by Dr.Richard J. 
Webby - Department of Infectious Diseases, St. Jude Children’s Research Hospital) 
In our analysis, POMxp demonstrated potent antiviral activity against x31 and PR8, two long-
established and now standard laboratory strains of influenza A virus. An important question was 
whether a similar level of antiviral activity would be evident against recent influenza isolates, 
including emerging viruses that present a threat to human health. To investigate this, POMxp 
activity was tested against reassortant influenza viruses expressing the HA and NA molecules of 
H5N1 isolates (the remaining viral components were derived from PR8). Compared with the 
effect against x31 and PR8, POMxp treatment resulted in only a minor reduction in the 
infectivity of rg-Dk/HN/02, rg-Dk/LS/06, and rg-JWE/HK/06. (Figure 16 B, C, D) 
However, the infectivity of rg-VN/04 was markedly reduced (Figure 16 A), resembling the effect 
of POMxp on x31. Thus, the susceptibility of variant H5N1 subtype viruses to PP treatment is 
modulated by the nature of the expressed HA and NA. In contrast to the results for x31 and PR8, 
the loss of infectivity after POMxp treatment of rg-VN/04 did not appear to be associated with a 
loss of HAg activity. Overall, results could be taken to indicate that the effect of PP exposure on 
HAg activity is not a predictor of effects on infectivity. However, a cautious interpretation is 
warranted because POMxp itself has HAg activity when the assay is performed in the absence of 
BSA. It is not possible to predict the consequences of potential multidirectional interactions 
when PP-treated viruses are combined with RBC in a BSA solution. In experiments in this 
section using H5N1 viruses, x31 was tested in parallel to ensure the reproducibility of earlier 
findings. The results for x31 matched those shown in Figure 16A. 
 



























































































































































Figure 16 A, B, C, D: The antiviral activity of POMxp against variant H5N1 influenza 
viruses. The following influenza viruses at the indicated titers were treated for 5 min at room 
temperature with different concentrations of POMxp (expressed as PP concentration): rg-VN/04 
(H5N1) at 5 x 10
7
 TCID50/ml (A), rg-Dk/HN/02 (H5N1) at 5 x 10
7
 TCID50/ml (B), rg-Dk/LS/06 
(H5N1) at 2.8 x 10
7
 TCID50/ml (C), rg-JWE/HK/06 (H5N1) at 1 x 10
7
 TCID50/ml (D).Infectious 
virus titers measured by TCID50 assay (filled squares, left axis) and hemagglutination titers (open 
squares, right axis) were determined after treatment.  




We used a new approach of the infectivity assay when evaluating the anti influenza virus activity 
of POMxp. For this new method, we made different concentration of filtered POMxp in PBS. 
The filtered POMxp concentration we used in our infectivity assay were 40%, 20%, 10%, 5%, 
2.5%, 1.25%, 0.625% in PBS. In this approach all the procedures were the same as the usual 
procedure of infectivity, except that we did not treat the samples at RT for 5 minutes. Also 
usually we add the sample and virus together into the wells containing monolayers but we added 
the sample first and then added the virus (equal amount of virus and sample) and after adding the 
sample and virus to the wells containing the monolayers of MDCK cells, we did the serial 
tenfold dilution. Rest of the procedure was the same. We observed that the viral titers were high 
for the different concentration of filtered POMxp. So we thought this is not the ideal approach. 
  
We also evaluated the toxicity of different concentration of filtered POMxp on monolayers of 
MDCK cells. We found that monolayer was better when we used filtered POMxp diluted in 
MEM1X with 5% FBS than with MEM1X with 0.3% BSA.Overall, our findings indicate that 
POMxp is not toxic to MDCK cells. 
4. Discussion: 
 
Our analysis using POMxp showed that brief treatment at room temperature with > 200 μg/ml 
PPs substantially reduced the infectivity of H1N1, H3N2, and H5N1 influenza viruses. 
Generally, the loss of infectivity was accompanied by loss of hemagglutinating activity. Electron  
microscopic examination of influenza particles neutralized by PP treatment identified a coating 
of amorphous material and some damage to virion integrity. Reassortant H5N1 viruses derived  





modulated by small changes in surface glycoproteins. We show that the PP component of 
pomegranates interacts directly with influenza virus particles and rapidly neutralizes infectivity. 
The antiviral activity of pomegranate PPs was potent against diverse influenza virus subtypes, 
including emerging viruses that threaten human health.  
Previous studies demonstrating the anti-influenza activity of PPs from other plant sources have 
provided evidence for a direct interaction of PPs with the viral HA and NA [Ehrhardt et al., 
2007; Nagai et al., 1992; Nakayama et al., 1993; Serkedjieva and Manolova, 1992; Song et al., 
2005]. Our analysis suggests that the accessibility of these molecules is impeded by PP 
treatment, but that at least some antigenic features remain intact. 
Direct virus neutralization by PPs may simply result from physical interference with the 
interaction between the viral HA and cell receptors. This mechanism is consistent with the loss 
of virus-mediated hemagglutination after PP treatment, as was clearly seen for x31 and PR8. 
However, loss of infectivity after PP treatment was not associated with loss of HAg activity for 
all influenza viruses tested, raising the possibility of additional mechanisms of neutralization. 
This is supported by our electron microscopic analysis of PP-treated x31, which indicated at least 
some degree of envelope damage. 
Pomegranate PPs were effective in reducing the infectivity of the H5N1 virus rg-VN/04. 
However, the effect was much smaller against three other H5N1 viruses, rg-Dk/HN/02 and rg-






entirely to the HA and NA molecules, since the H5N1 viruses were reassortants that expressed  
only the HA and NA of the original isolates and did not differ in the remaining viral components. 
Rg-Dk/HN/02, rg-Dk/LS/06, and rg-JWE/HK/06 were derived from avian H5N1 isolates, 
whereas rg-VN/04 was derived from an isolate from a fatal human case. This raises the 
possibility that features of the surface glycoproteins of influenza viruses adapted to maintenance 
in avian reservoirs may also confer resistance to the effects of PPs. It will be of interest to 
determine whether influenza isolates that are resistant to direct inactivation by PPs remain 
susceptible to the antiviral activity of PPs that operates during intracellular replication [Haidari et 
al., 2009].  
PP preparations derived from plants are typically a complex mixture of molecular forms. There 
is evidence for differences in the antiviral activity of individual PP compounds [Haidari et al., 
2009] and synergistic activity by PP mixtures [Song et al., 2005]. Presumably, the biochemical 
reactivity of PPs and their interactions with proteins and lipids play an important role [Diniz et  
al., 2008; Soares et al., 2007]. However, the molecular interactions that are the basis for the 
antiviral activity of PPs and how these relate to the characteristics of specific PPs are not well 
understood [Song et al., 2005].  
Our analysis and other studies [Ehrhardt et al., 2007; Serkedjieva, 2003] indicate that reactivity 
with PPs is also influenced by relatively small changes in the molecular features of viral surface 
proteins. PP binding to cell surface molecules have been described [Williamson et al., 2006].  
Nevertheless, there is evidence for some selectivity in PP reactivity and preferential binding to 




Studies of mouse models have shown that PP administration to the lung reduced the effects of 
influenza infection without toxicity to the host [Droebner et al., 2007; Nagai et al., 1992; 
Serkedjieva et al., 2008]. Interestingly, nasopharyngeal administration of pomegranate extracts is 
a Cuban folk medicine remedy for influenza [Vidal et al., 2003]. Our analysis emphasizes the 
possibility that PPs derived from Pomegranate Powder Extracts and other plant sources may be 























































































The decay of organic matter generates an extremely heterogeneous mixture of organic molecules 
referred to as humic substances. They are sub-classified on the basis of solubility characteristics. 
The Fulvic Acid (FA) fraction of humic substances includes a variety of low molecular weight 
acidic molecules that are soluble in water under all pH conditions. The current study was 
undertaken to evaluate the direct anti-influenza activity of Fulvic Acid (FA).A standard dose of 
infectious virus was incubated with the different concentration of Fulvic Acid (FA). Viral 
infectivity was measured by titration in susceptible MDCK cells, and hemagglutinating activity 
was determined using chicken red blood cells. Our findings demonstrate rapid anti-influenza 




A network of researchers have been investigating the antiviral properties of a formulation called 
Secomet V, whose active ingredient is fulvic acid, which is a complex mixture of compounds 
arising from decomposing organic matter. Antiviral activity of fulvic acid containing Secomet V 
against poxviruses and SARS has been demonstrated [ Kotwal et al., 2006].In the current study, 
we investigated the direct anti-influenza virus activity of fulvic acid. We demonstrate that 
components of fulvic acid rapidly inactivate influenza virus. Our findings suggest that 
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2. Materials and Methods: 
 
2.1. Fulvic Acid: 
We used a formulation called Secomet V which was given / sent by Dr.Girish J. Kotwal. It has 
been reported to have a broad spectrum antiviral properties [Kotwal et al., 2006] and was 
subsequently revealed a year later by Stefan Coetzee from Fulvimed Pvt. Ltd. to have Fulvic 
Acid as the major active ingredient.  
Chemical Properties of Fulvic Acid: 
The bioactive Fulvic Acid found in the formulation was separated by ultra filtration using a 
3000 Da filter and column chromatography and found to be in the range of 200–600 Da; with the 
peak activity observed around fractions corresponding to 113, 226 and 452 Da indicating that the 
active compounds may be repeats of a monomeric unit of 113 Da (Kotwal, unpublished). Fulvic 
acids are light yellow to yellow-brown in color. Physical and chemical analyses show that the 
formulation is acidic (around pH 2) and heat stable (survives autoclaving), and that the levels of 
iron and arsenic are well below the permissible levels [Kotwal, 2008]. 
2.2 Chicken Red Blood Cells: 
 
As described in Chapter 2 
 
2.3 Phosphate buffered saline (PBS): 
 
As described in Chapter 2 
 
2.4. Viruses and viral titration: 






2.5. Treatment of virus with Fulvic Acid and evaluation of antiviral activity: 
Confluent monolayers of MDCK cells for viral titration were grown in 96-well tissue culture 
plates and were washed once with serum-free MEM before use. MEM containing 0.3% bovine 
serum albumin (Sigma) and 1 μg/ml L-(toslyamido 2-phenyl) ethyl chloromethyl ketone 
(TPCK)-treated trypsin [Worthington, Lakewood, NJ] was added to the wells and used for 
dilution of treated virus. Influenza virus at 5 x 10
7
 TCID50/ml was combined with different 
concentrations of FA diluted in PBS, and incubated for 5 min at room temperature.  
Immediately following incubation, treated virus was serially diluted 10-fold in triplicate wells 
containing MDCK cell monolayers, and plates were incubated for 2 days at 37°C with 5% CO2. 
Wells positive for virus growth were identified by the presence of hemagglutinating activity in 
the supernatant by using a fresh 96-well round bottom plate. We transferred 50μl of supernatant 
from the original plate to the fresh 96-well round bottom plate, carefully not disrupting the 
MDCK monolayer at the bottom of the wells, from the top row to the bottom row of the plate. 
Added the 50μl of 0.5% CRBC to all the wells. The plates were briefly agitated with hand and 
set the plate on the bench for 30 minutes to one hour at room temperature.  
After the incubation, wells positive for virus growth were identified by the presence of 
hemagglutinating activity. In the absence of hemagglutinating activity, red blood cells roll to the 
bottom of the wells and form small round pellets, whereas no pellets are visible when the cells 
are agglutinated and 50% tissue culture infective dose (TCID50) titers were calculated by the 





The HAg activity of influenza viruses was also evaluated immediately after treatment with 
different concentrations of FA as described above. Immediately following incubation with FA 
solutions, serial 2-fold dilutions of treated samples were prepared with PBS in 96-well round- 
bottom plates (50 μl/well).  
 
An equal volume of 0.5% chicken RBC was added to each well, plates were briefly agitated, and 
hemagglutination was scored after 30 min to one hour incubation at room temperature. After the 
incubation, hemagglutiantion was scored. In the absence of hemagglutinating activity, red blood 
cells roll to the bottom of the wells and form small round pellets, whereas no pellets are visible 





3.1. Fulvic Acid eliminate influenza virus infectivity and hemagglutinating activity 
 
Experiments tested FA for direct antiviral activity against influenza x31 and PR8. The virus was 
treated for 5 min at room temperature with different concentrations of FA and titers of infectious 
virus and hemagglutinating activity were determined .We observed that the viral infectivity and 
the hemagglutinating activity were inhibited in a dose (FA concentration) dependent manner 
indicating that FA possibly blocks entry of virus by interacting with the sugar or the lipid moiety 


































































































































































The hemagglutinating activity of the virus was inhibited indicating that fulvic acid possibly 
blocks entry of the virus by interacting with the sugar or lipid moiety or both of surface 
glycoproteins of virus. Most of the time, formulation containing fulvic acid neutralized the 
infectivity of the virus in a dose-dependent manner when treated for  5 minutes at room 
temperature possibly by interacting with sugar chains on the viral surface protein and serving as 
an entry inhibitor. 
 
A formulation consisting of fulvic acid, a complex mixture of compounds was previously  
reported to render vaccinia virus, HIV and SARS virus non-infectious. Recently, fulvic Acid has 
been shown to inactivate genetically diverse strains of influenza including H5N1, further 
confirming the broad spectrum nature of this agent. How fulvic acid will be used in developing a 
vaccine achieving sterilizing immunity or prophylaxis needs to be researched [Kotwal, 2008]. 
 
We suggest that compounds with antiviral activity from fulvic acid neutralize the infectivity of 
diverse enveloped viruses and a number of subtypes of a given enveloped virus, indicating 
potential for development as a treatment option that can be broadly effective against pandemic 
























































CHAPTER VI   CONCLUSION 
 
 
All of the extracts of Pomegranate and Fulvic Acid had rapid antiviral activity. Both the 
Pomegranate Juice and the Pomegranate Liquid Extract has anti-influenza virus activity that 
was distinct from the effect of the acidic pH of the test materials. POMxp at a concentration 
of > 200 μg/ml PPs substantially reduced the infectivity of H1N1, H3N2, and H5N1 
influenza viruses. Generally, the loss of infectivity was accompanied by loss of 
hemagglutinating activity. Electron microscopic examination of influenza particles 
neutralized by PP treatment identified a coating of amorphous material and some damage to 
virion integrity. Reassortant H5N1 viruses derived from avian isolates were less affected by 
PP treatment, indicating that PP susceptibility is modulated by small changes in surface 
glycoproteins.  
We show that the PP component of pomegranates interacts directly with influenza virus 
particles and rapidly neutralizes infectivity. The antiviral activity of pomegranate PPs was 
potent against diverse influenza virus subtypes, including emerging viruses that threaten 
human health.Previous studies demonstrating the anti-influenza activity of PPs from other 
plant sources have provided evidence for a direct interaction of PPs with the viral HA and 
NA [Ehrhardt et al., 2007; Nagai et al., 1992; Nakayama et al., 1993; Serkedjieva and 
Manolova, 1992; Song et al., 2005]. Our analysis suggests that the accessibility of these 






Direct virus neutralization by PPs may simply result from physical interference with the 
interaction between the viral HA and cell receptors. This mechanism is consistent with the 
loss of virus-mediated hemagglutination after PP treatment, as was clearly seen for x31 and 
PR8. However, loss of infectivity after PP treatment was not associated with loss of HAg 
activity for all influenza viruses tested, raising the possibility of additional mechanisms of 
neutralization. This is supported by our electron microscopic analysis of PP-treated x31, 
which indicated at least some degree of envelope damage. 
Pomegranate PPs were effective in reducing the infectivity of the H5N1 virus rg-VN/04. 
However, the effect was much smaller against three other H5N1 viruses, rg-Dk/HN/02 and 
rg-Dk/LS/06(in particular) and rg-JWE/HK/06. Differences in susceptibility can be attributed 
entirely to the HA and NA molecules, since the H5N1 viruses were reassortants that 
expressed only the HA and NA of the original isolates and did not differ in the remaining 
viral components. Rg-Dk/HN/02, rg-Dk/LS/06, and rg-JWE/HK/06 were derived from avian 
H5N1 isolates, whereas rg-VN/04 was derived from an isolate from a fatal human case. This 
raises the possibility that features of the surface glycoproteins of influenza viruses adapted to 
maintenance in avian reservoirs may also confer resistance to the effects of PPs.  
It will be of interest to determine whether influenza isolates that are resistant to direct 
inactivation by PPs remain susceptible to the antiviral activity of PPs that operates during 





PP preparations derived from plants are typically a complex mixture of molecular forms. 
There is evidence for differences in the antiviral activity of individual PP compounds 
[Haidari et al., 2009] and synergistic activity by PP mixtures [Song et al., 2005]. Presumably, 
the biochemical reactivity of PPs and their interactions with proteins and lipids play an 
important role [Diniz et al., 2008; Soares et al., 2007]. However, the molecular interactions 
that are the basis for the antiviral activity of PPs and how these relate to the characteristics of  
specific PPs are not well understood [Song et al., 2005].  
Our analysis and other studies [Ehrhardt et al., 2007; Serkedjieva, 2003] indicate that 
reactivity with PPs is also influenced by relatively small changes in the molecular features of 
viral surface proteins. PP binding to cell surface molecules have been described [Williamson 
et al., 2006]. Nevertheless, there is evidence for some selectivity in PP reactivity and 
preferential binding to viral compared with host cell molecules [Nagai et al., 1992; 
Serkedjieva et al., 2008]. 
Studies of mouse models have shown that PP administration to the lung reduced the effects 
of influenza infection without toxicity to the host [Droebner et al., 2007; Nagai et al., 1992; 
Serkedjieva et al., 2008]. Interestingly, nasopharyngeal administration of pomegranate 
extracts is a Cuban folk medicine remedy for influenza [Vidal et al., 2003]. Our analysis 
emphasizes the possibility that PPs derived from pomegranates and other plant sources may 
be utilized to combat influenza and other viral infections 
Studies have shown that virus neutralizing compounds in the body fluid could neutralize 
viruses in the blood stream and elicit an immune response to the neutralized authentically 
folded virus particle and thus facilitate development of a potentially protective immunity 
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[Kotwal and Kulkarni,1997].So the active antiviral components from Pomegranate Extracts 
and from Fulvic Acid could neutralize the infectivity of diverse viruses and a number of 
subtypes, indicating the potential for development of a treatment option that can be broadly 
effective against pandemic viruses like HIV, potentially pandemic viruses like influenza and 
carcinogenic viruses like HBV and HCV.      
Thus the identification of optimally active components or combinations of components in 
Pomegranate Extracts and Fulvic Acid may lead to natural, rapidly active, broad-spectrum 
preparations for inhalation or topical application that aid in the control of seasonal and 
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